Human umbilical cord blood cells (HUCBCs), a prolific source of non-embryonic or adult stem cells, have emerged as effective and relatively safe immunomodulators and neuroprotectors, reducing behavioral impairment in animal models of Alzheimer's disease (AD), Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, spinal cord injury, and stroke. In this report, we followed the bioavailability of HUCBCs in AD-like transgenic PSAPP mice and nontransgenic Sprague-Dawley rats. HUCBCs were injected into tail veins of mice or rats at a single dose of 1 × 10 6 or 2.2 × 10 6 cells, respectively, prior to harvesting of tissues at 24 h, 7 days, and 30 days after injection. For determination of HUCBC distribution, tissues from both species were subjected to total DNA isolation and polymerase chain reaction (PCR) amplification of the gene for human glycerol-3-phosphate dehydrogenase. Our results show a relatively similar biodistribution and retention of HUCBCs in both mouse and rat organs. HUCBCs were broadly detected both in the brain and several peripheral organs, including the liver, kidney, and bone marrow, of both species, starting within 7 days and continuing up to 30 days posttransplantation. No HUCBCs were recovered in the peripheral circulation, even at 24 h posttransplantation. Therefore, HUCBCs reach several tissues including the brain following a single intravenous treatment, suggesting that this route can be a viable method of administration of these cells for the treatment of neurodegenerative diseases.
INTRODUCTION
Alzheimer's disease (AD), the most prevalent progressive form of age-related dementia, is pathologically characterized by the deposition of amyloid-b-peptide (Ab) as amyloid plaques in the brain parenchyma as well as neurofibrillary tangles within neurons. Ab is known to be produced via the amyloidogenic pathway, involving the sequential cleavage of amyloid precursor protein (APP) by band g-secretases within the cell membrane (24, 25, 30) . Due to widespread cellular atrophy that occurs in both cortical and subcortical brain regions, AD patients suffer cognitive and emotional dysregulation that progresses to an inability to independently and safely perform acts of daily living (ADL) (21, 22) . The dementia patient population, according to the World Alzheimer Report 2010, has reached a record high of 35.6 million and is expected to increase to 65.7 million by 2030 and 115.4 million by 2050. Development of more effective treatments or prophylaxes is therefore crucial.
Previous studies from our laboratory and others have shown that multiple small intravenous administrations of human umbilical cord blood cells (HUCBCs), specifically cells derived from the mononuclear fraction (HUCBMNCs), reduce cognitive impairment, Ab levels, b-amyloid plaques, amyloidogenic APP processing, and reactive microgliosis in mouse models of AD (PSAPP and Tg2576 mice) (4, 13, 20) . At a single high dose, HUCBC treatment can even extend the life span of AD mice overexpressing human Swedish APP695 (7). Additional studies indicate that HUCBCs improve therapeutic outcomes in rodent models of Parkinson's disease (PD) (6), amyotrophic lateral sclerosis (ALS) (11,12), types 1 and 2 diabetes (8, 9) , lupus (10), traumatic brain and spinal cord injury (5, 11, 18) , and stroke (3, 11) . While the therapeutic consequence of these HUCBCs is of unquestionable medical merit, it is equally important to characterize which organs these cells migrate to and how long they maintain a presence in these tissues. In this report, we followed the biodistribution of HUCBCs following a single intravenous treatment in PSAPP mice and nontransgenic Sprague-Dawley rats. Elucidating the homing proclivity and longevity of HUCBCs following this route of administration is useful for elucidating its potential effectiveness and mechanism of action in the treatment of neurodegenerative disorders.
MATERIALS AND METHODS

Animals and Institutional Approvals
All procedures described herein were in accordance with the animal protocol approved by the University of South Florida (USF) Institutional Animal Care and Use Committee. PSAPP transgenic mice and Sprague-Dawley rats, both at 7 months of age, were obtained from the Jackson Laboratory (Bar Harbor, ME, USA), maintained on a 12-h light/12-h dark cycle at ambient temperature and humidity and allowed standard rodent chow and water ad libitum. Saneron used de-identified cord blood donations from commercial sources for the processing of the U-CORD-CELL™.
HUCBC Preparation
HUCBCs (95-98% mononuclear cells) were graciously donated by Saneron CCEL Therapeutics Inc. (Tampa, FL, USA). Briefly, the mononuclear fraction of HUCBCs (U-CORD-CELL TM ) was obtained from donated cord blood using a Ficoll-Paque density gradient solution (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) and stored at −210°C. Prior to transplantation, HUCBCs were thawed at 37°C for 4 min, washed in phosphate-buffered saline (PBS), assessed for viability (>93%) using the trypan blue (Sigma-Aldrich, St. Louis, MO, USA) exclusion method (hemocytometer), and suspended in PBS to achieve a final desired cell concentration of 1.0-2.2 × 10 6 cells per 100 ml.
HUCBC Infusion
Seven-month-old PSAPP mice (n = 22; 11 males, 11 females) or nontransgenic Sprague-Dawley rats (n = 22; 11 males, 11 females) were randomly injected in the right tail vein with HUCBCs at 1.0 × 10 6 or 2.2 × 10 6 cells/100 µl, respectively, or 100 µl PBS (Fisher Scientific, Pittsburgh, PA, USA) as control. At 24 h, 7 days, or 30 days after injection (n = 6 for each time point, n = 4 control), animals were anesthetized with pentobarbital (Sigma-Aldrich) (50 mg/kg), and the hindlimbs and peripheral blood were harvested for determination of HUCBCs in bone marrow and blood. Transcardiac perfusion with ice-cold PBS was then performed, followed by harvesting of the liver, lung, spleen, kidney, heart, spinal cord, brain, and gonads. These organs were immediately snap frozen in liquid nitrogen for polymerase chain reaction (PCR) analysis for the presence of human DNA.
PCR Analysis
The presence of human DNA in murine and rodent tissues was used as a screen to determine the biodistribution of HUCBCs. Total purified DNA was obtained from tissue samples using a DNeasy Blood and Tissue kit (Qiagen, Valencia, CA, USA) and quantified using a NanoDrop 2000C spectrophotometer (ThermoFisher, Wilmington, DE, USA). DNA was replicated using nested PCR techniques (total volume 25 µl), specifically for the presence of the human glycerol-3-phosphate dehydrogenase (HG3PDH) gene using appropriate primers (sense: 5¢-GGCTGGGACTCATGGAGAT-3¢ and antisense: 5¢-CG GGTAAGTCGTTGA-GAAAG-3¢) (28) An additional nested PCR was performed with primers (sense: 5¢-TC TTGGAGAGCTGTGGTGTTG-3¢ and antisense: 5¢-GT TACCTGAAAGGACTGC-3¢) specific to the product of the first PCR reaction to further account for any nonspecific binding and PCR products (28) . DNA presence in the various organs was resolved using a 1% agarose gel (Invitrogen, Grand Island, NY, USA), stained with ethidium bromide (Sigma-Aldrich) and visualized using UV translumination.
RESULTS
In order to determine the biodistribution of HUCBCs after a single intravenous injection, the presence of HG3PDH DNA in the blood, bone marrow, brain, spinal cord, spleen, kidney, liver, heart, lung, and gonads was determined at 24 h, 7 days, and 30 days after the HUCBC administration in PSAPP mice and Sprague-Dawley rats. Within 24 h, HG3PDH DNA was observed by PCR analysis in every organ except blood for mice and remained in the bone marrow, brain, kidney, liver, heart, and lungs after 30 days (Table 1 ). For rats, the human DNA was observed in the brain, spinal cord, spleen, kidney, liver, and heart within 24 h and remained in the brain, spinal cord, kidney, and liver after 30 days (Table 2) . Interestingly, for rats, the human DNA was first detectable in the bone marrow at 30 days and in gonads at 7 days. All animals survived for the entirety of the transplantation periods with no indication of aberrant cell growth or tumor formation. Overall, these results indicate that HUCBCs distribute to several organs, including the brain and spinal cord, within 24 h after a single intravenous injection and can remain in these organs for up to 30 days.
DISCUSSION
In this report, we show that HUCBCs distribute widely throughout the body within 24 h after a single intravenous injection and can remain in several tissues, including the brain, even after 30 days. Since an AD mouse model (PSAPP mice) was used in these studies, data also indicate that peripherally administered HUCBCs offer a viable treatment for this neurodegenerative disease. Previous studies have shown that PSAPP mice treated from 7 months of age with infused bone marrow mesenchymal stem cell (BM-MSC) suspensions biweekly for 1 month exhibited reduced amyloid-b deposition and rescued memory deficits (15). Further studies from our laboratory indicated that multiple monthly low-dose injections of HUCBCs into PSAPP mice reduce cognitive impairment, Ab levels/b-amyloid plaques, amyloidogenic APP processing, and reactive microgliosis (4) . The PSAPP transgenic mouse model of amyloid-b deposition has shown numerous benefits in characterizing the role of Ab in cognitive impairment and pathogenesis in Alzheimer's disease (16, 31) . In order to determine the biodistribution of peripherally administered HUCBCs, and thus elucidate their mechanism of action, the present study determined the expression of HG3PDH DNA in several tissues after a single intravenous injection. The results indicate that this route of administration can be sufficient to have a direct therapeutic effect in several tissues, including the brain, for up to 1 month after administration.
Interestingly, we observed the disappearance of HUCBC DNA in the rat kidney at 7 days and reemergence of a positive signal at the later 30-day time point. This disappearance and reemergence of the HUCBC signal is most likely due to the unique properties of these cells. Initially, a small population of HUCBCs migrated from circulation into the kidney and were detectable using PCR techniques, at the 24-h time point. These cells remain proximal to the vessels that they extravasate from and possess the ability to reenter the circulation at later time points (12) . Sometime between the 24-h and 7-day time point, a majority of the cells either reemerged into circulation or were degraded in the microenvironment of the kidney. Furthermore, at some point between the 7 days and 30 days, a few of the remaining HUCBCs emerged back into circulation and migrated from the blood into the kidney. This results in the return of a positive signal for the presence of HUCBCs in the rat kidney. Since they do not migrate very far from the vessels, another possibility is that we may simply be detecting the DNA of these cells that have died in the tissue. The dead/ dying cells or their DNA may be expelled back into circulation and filtered out by the kidney for clearance. As a result, we may be detecting the HG3PDH DNA from these dead or dying cells.
HUCBCs have been verified as a prolific source of non-embryonic or adult stem cells and have shown therapeutic potential in animal models of AD, multiple sclerosis (MS), ALS, age-related macular degeneration, PD, traumatic brain injury (TBI), spinal cord injury (SCI), and stroke (3) (4) (5) (11) (12) (13) (14) 18, 20) . HUCBCs can be safely cryopreserved and remain viable for years. Apart from retaining a primitive ontogeny, HUCBCs have not Nontransgenic Sprague-Dawley rats were given a single injection of 2.2 × 10 6 HUCBCs via the tail vein. Twenty-four hours after injection, human DNA was detectable in the brain, spinal cord, spleen, kidney, liver, and heart, but not in blood, bone marrow, lung, or gonad. By 30 days, human DNA was found in the bone marrow, brain, spinal cord, kidney, liver, and gonad, while the blood, spleen, heart, and lung were negative (n = 6 per group).
been exposed to immunologic challenge, thus retaining an immunologically immature phenotype (27) . It is also reported that HUCBC progenitors have as much as four times as many CD34 + cells and up to an eightfold proliferative capacity compared to similar cells in the bone marrow (1) . Moreover, these cells form larger colonies, possess higher cell cycle rates, and have fairly long telomere lengths, confirming their immature status. Furthermore, with greater availability, weak immunogenicity, and reduced probability of arbitrating viral transmission, HUCBCs may represent the best alternative for cell-based therapy (17). The therapeutic benefits of HUCBC treatment seem to evoke modulation of inflammatory processes both peripherally and centrally (2, 23, 26) . In studies that employed the middle cerebral artery occlusion (MCAO) animal stroke model, it was observed that the spleen is one of the primary vessels of immune cells that become activated and migrate in response to the progression of stroke pathology, eventually leading to cell death in the ischemic penumbra due to chronic inflammation. When HUCBCs are administered after the ischemic MCAO event, the immune cell activation and migration, as well as the massive delayed cell death observed in the penumbra, can be prevented (28, 29) . In vitro, it was shown that the supernatant from cultured HUCBCs promotes survival of NT2 neural cells cultured under cell stress conditions (5). Moreover, it has been shown in animal studies that HUCBC infusion mediates recovery after brain injury within days (19,23), a time period too short for reinnervation, suggesting transplanted cells may not act at the site of brain injury by rejuvenating new cells, but may confer therapeutic effects through paracrine factors.
In conclusion, we have demonstrated that a single low dose of HUCBCs can be sufficient in promoting therapeutic benefits without the possibility of concomitant aberrant cell growth or tumor formation. However, due to the low dose of HUCBCs administered and eventual loss of these cells in key organs, such as the spleen, the use of multiple low-dose infusions may be necessary to prolong the therapeutic benefit of these cells (4), while still benefiting from a lower chance of ectopic cell growth. The exact mechanism of efficacy with multiple low-dose HUCBC infusions in AD patients remains to be elucidated. In addition, further studies investigating which specific HUCBC cell type(s) and/or possible secreted factors that are capable of modulating the neuroinflammation observed with AD, stroke, ALS, and MS are essential.
